EUVIMEDEUVIMED entdecken
Crossref

Targeting GPX4-Dependent Ferroptosis via a Dihydroartemisinin-Conjugated Cross-Linked Lipoic Acid Nanodrug for Endometrial Carcinoma Therapy

Qi Cao iD, Xiao Wu, Juan Tan, Hanying Xu, Ying Zhang, Yang Hu, Yuxi Chen, Shiyong Zhang iD, Tian Tang

Bioconjugate Chemistry · 16.07.2025 · 36 (7) · 1541-1552

DOI: 10.1021/acs.bioconjchem.5c00256 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, online erschienen am 04.07.2025. Verfasst von Qi Cao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Reproductive Medical Center, West China Second University Hospital, Sichuan University; Key Laboratory of Birth Defects and Related Dis…. Hauptthemen laut MEDLINE: Ferroptosis, Artemisinins, Thioctic Acid, Endometrial Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endometrial cancer (EC) is a significant global cause of cancer-related mortality. Chemoresistance is a major challenge in treating advanced or recurrent EC, necessitating the search for new anti-EC drugs. Dihydroartemisinin (DHA)-induced ferroptosis shows promise as a therapy for EC, but its poor solubility and insufficient antitumor potency hinder its clinical use. A novel nanodrug delivery system, DHA@cLAVs, was developed using cross-linked lipoic acid to enhance DHA solubility and antitumor efficacy. Benefiting from the pro-oxidant effects of lipoic acid on tumor cells and its improved water solubility, DHA@cLAVs outperformed DHA alone, showing promising ferroptosis-based antitumor effects via the c-jun/c-fos-GPX4 pathway in both in vitro and in vivo experiments, offering promising prospects for endometrial carcinoma treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisArtemisininsThioctic AcidEndometrial NeoplasmsPhospholipid Hydroperoxide Glutathione PeroxidaseAntineoplastic AgentsNanoparticlesHumansFemaleAnimalsCell Line, TumorMice

Substanzen

artenimolArtemisininsThioctic AcidPhospholipid Hydroperoxide Glutathione PeroxidaseAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Reproductive Medical Center, West China Second University Hospital, Sichuan University; Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Educatio…
  • West China School of Medicine, Sichuan University, Chengdu 610041, Sichuan, P. R. China.
  • College of Biomedical Engineering and National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, Sichuan, P. R. China.
  • West China College of Pharmacy, Sichuan University, Chengdu 610041, Sichuan, P. R. China.

ORCID-Profile: Qi Cao, Shiyong Zhang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Cao, Q., Wu, X., Tan, J., Xu, H., Zhang, Y., Hu, Y., Chen, Y., Zhang, S., & Tang, T. (2025). Targeting GPX4-Dependent Ferroptosis via a Dihydroartemisinin-Conjugated Cross-Linked Lipoic Acid Nanodrug for Endometrial Carcinoma Therapy. Bioconjugate Chemistry, 36(7), 1541-1552. https://doi.org/10.1021/acs.bioconjchem.5c00256

Vancouver

Cao Q, Wu X, Tan J, Xu H, Zhang Y, Hu Y, et al. Targeting GPX4-Dependent Ferroptosis via a Dihydroartemisinin-Conjugated Cross-Linked Lipoic Acid Nanodrug for Endometrial Carcinoma Therapy. Bioconjugate Chemistry. 2025;36(7):1541-1552. doi:10.1021/acs.bioconjchem.5c00256

BibTeX
@article{Cao2025,
  author = {Cao, Qi and Wu, Xiao and Tan, Juan and Xu, Hanying and Zhang, Ying and Hu, Yang and Chen, Yuxi and Zhang, Shiyong and Tang, Tian},
  title = {Targeting GPX4-Dependent Ferroptosis via a Dihydroartemisinin-Conjugated Cross-Linked Lipoic Acid Nanodrug for Endometrial Carcinoma Therapy},
  journal = {Bioconjugate Chemistry},
  year = {2025},
  volume = {36},
  number = {7},
  pages = {1541--1552},
  doi = {10.1021/acs.bioconjchem.5c00256}
}
Kostenlos starten →